Hypha Discovery: Experts in Metabolite Synthesis
Purification
Structure elucidation
Natural Products

Supporting pharmaceutical and agrochemical companies globally

Your trusted partner in pharmaceutical and agrochemical R&D

What we do

Hypha Discovery is a specialist CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and late-stage derivatives of drugs and agrochemicals in discovery and development.

We are experts in the scalable synthesis, purification and identification of drug metabolites and oxidised derivatives of lead compounds, and also possess a wealth of experience in the production, purification and structure elucidation of natural products.

We also use our purification expertise to isolate and identify manufacturing impurities and degradation products.

Solutions for metabolite synthesis

Hypha Discovery offer a comprehensive suite of techniques for provision of even the most difficult-to-synthesise metabolite, comprising chemical synthesis, recombinant enzymes such as PolyCYPs, microbial biotransformation, mammalian liver fractions as well as the purification of metabolites from biological matrices. We are also experts in the structure elucidation of metabolites by NMR spectroscopy.

Chemical Synthesis

Late-stage chemical glucuronidation

Mammalian biotransformation

Panels of liver S9s / microsomes

Microbial biotransformation

Proven panels of bacteria and fungi

Purification & structure elucidation

COAs, acquisition / interpretation of NMR data

Recombinant enzymes

PolyCYPs, hrCYPs, AOX, FMOs

PolyCYPs kits

PolyCYPs+ screening kits comprise 18 PolyCYP isoforms together with the addition of other phase 1 enzymes. Human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3) are included in the kit, with the other human FMO isoforms, available separately at Hypha.

Inclusion of multiple PolyCYPs isoforms broadens coverage of reactions, and which have been proven to produce human and other mammalian CYP-derived metabolites including multi-step metabolites and metabolites of low turnover drugs.

Simple, Effective, Scalable

Produce CYP, AOX & FMO metabolites

Generate multiple hydroxylated and other oxidised derivatives of lead compounds in parallel

About Us

Delivering a first class service to our clients worldwide

Expertise

Hypha Discovery is your trusted global partner. We are go-to experts for metabolite solutions and have worked with many of the top pharma and agrochemical companies worldwide to deliver projects.

Flexibility

We will work with you to design a custom solution that meets your needs and which can be adapted in response to project milestones.

Service

We pride ourselves on our client focused approach. Our scientists will work with you to personally deliver your project.

We contacted Hypha Discovery to generate specific phase I and phase II metabolite standards in sufficient quantities and purity to allow structural confirmation and quantitation. Hypha exceeded expectations, providing 60mg of a phase I metabolite and over 100mg of a phase II metabolite at high purity. Hypha’s team was a pleasure to work with and communicative and responsive throughout the process. We will undoubtedly be working with Hypha Discovery in the future.

Jason Boer, Associate DirectorIncyte Corporation, Wilmington, USA

The services conducted by Hypha allowed Alkermes to enhance our “Late Stage Functionalization” efforts to rapidly expand our SAR understanding inside projects. In particular, the PolarExplorer work allowed facile generation of hydroxylated compounds possessing a complex molecular core.
We look forward to engaging Hypha in the future because their team is professional, and their services complement our internal synthetic efforts for delivering new molecules.

Brian Aquila, Director of Medicinal ChemistryAlkermes, Waltham MA, USA

Hypha Discovery did a fantastic job synthesizing N- and O- glucuronides of our clinical stage drug substance. The project updates were detailed, our questions were answered in a timely manner, and the overall timeline was maintained. Hypha was highly recommended to us and I would not hesitate to recommend them to a colleague

Joshua Day Ph.D, Director of ChemistryCrestone, Inc., Colorado, USA

Q3 2024 Newsletter – Metabolism of degraders, gut metabolites, qNMR and more

Our Q3 2024 newsletter focusses on metabolism of degraders, gut metabolites, qNMR, as well as our latest blog articles and paper picks.

Q2 2024 Newsletter – Focus on N-glucuronidation

Our Q2 2024 newsletter focusses on UGT1A4 mediated N-glucuronidation of drugs and how to access these metabolites.

Q4 2023 Newsletter – Late-stage oxidation and deoxyfluorination

Our Q4 2023 newsletter looks at Hypha’s new late-stage oxidation and deoxyfluorination techniques for blocking metabolic soft spots.

Events

Meet us at one of the conferences we’ll be attending this year.

Blog

Check out our “Metabolite Tales” blog articles on interesting aspects around drug metabolism and medicinal chemistry.

Brochures

Access brochures on drug metabolite synthesis, Hypha’s one-stop metabolite shop, the PolyCYPs platform and PolarExplorer.

Ready to begin? Our scientists are available to talk through your requirements

Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.